pitolisant

Ligand id: 8924

Name: pitolisant

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 2
Hydrogen bond donors 0
Rotatable bonds 8
Topological polar surface area 12.47
Molecular weight 295.17
XLogP 3.94
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Pitolisant was initially granted orphan designation as a treatment for excessive daytime sleepiness and cataplexy in patients with narcolspey in the US and across Europe. In March 2016, pitolisant received EMA marketing authorisation for the treatment of narcolepsy [2]. Phase 3 trial results were reported in 2017 [10]. It was 2019 before the FDA approved this drug for the same indication as covered by the EMA marketing authorisation.
Mechanism Of Action and Pharmacodynamic Effects
Preclinical pharmacology of this compound is reported in [4-5], and its clinical potential is discussed in [1,3,9].
External links